Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protalix BioTherapeutics Q3 EPS $0.03 Misses $0.06 Estimate, Sales $17.673M Miss $17.866M Estimate

Author: Benzinga Newsdesk | November 13, 2025 06:51am
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 45.45 percent. This is unchanged from the same period last year. The company reported quarterly sales of $17.673 million which missed the analyst consensus estimate of $17.866 million by 1.08 percent. This is a 1.59 percent decrease over sales of $17.959 million the same period last year.

Posted In: PLX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist